Philadelphia gene therapy developer, backed by $250M, makes first acquisition, Hamilton’s Empirica Therapeutics

Empirica logo

Century Therapeutics today announced its acquisition of Empirica Therapeutics to leverage its iPSC-derived allogeneic cell therapies against glioblastoma (GBM). “We are pleased to welcome the Empirica team to the Century family. Their deep expertise and unique capabilities will allow us to accelerate efforts to develop iPSC derived immune effector cell products designed to treat and […]

Our website uses cookies to ensure you get the best experience. Learn more about the policy